I also discussed the example of a different class of agents called Werner helicase inhibitors, this time in patients with tumors with either MSI high or deficiency in MMR. And what we have seen is that these Werner helicase inhibitors are generally well-tolerated, mainly with GI toxicities. And they have led to patient benefit with a high disease control rate of approximately 70% and an overall response rate of about 15%...
I also discussed the example of a different class of agents called Werner helicase inhibitors, this time in patients with tumors with either MSI high or deficiency in MMR. And what we have seen is that these Werner helicase inhibitors are generally well-tolerated, mainly with GI toxicities. And they have led to patient benefit with a high disease control rate of approximately 70% and an overall response rate of about 15%. So there are different trials that are currently ongoing, mainly in combinations, either, for example, with immunotherapy agents such as pembrolizumab or with standard of care agents such as bevacizumab.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.